Seer, Inc. (SEER)

NASDAQ: SEER · Real-Time Price · USD
2.290
+0.010 (0.44%)
Nov 20, 2024, 4:00 PM EST - Market closed
0.44%
Market Cap 135.03M
Revenue (ttm) 14.61M
Net Income (ttm) -82.66M
Shares Out 58.97M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 261,374
Open 2.280
Previous Close 2.280
Day's Range 2.230 - 2.330
52-Week Range 1.510 - 2.500
Beta 1.46
Analysts Hold
Price Target 3.00 (+31.0%)
Earnings Date Nov 6, 2024

About SEER

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratori... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 147
Stock Exchange NASDAQ
Ticker Symbol SEER
Full Company Profile

Financial Performance

In 2023, Seer, Inc.'s revenue was $16.66 million, an increase of 7.54% compared to the previous year's $15.49 million. Losses were -$86.28 million, -7.20% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SEER stock is "Hold" and the 12-month stock price forecast is $3.0.

Price Target
$3.0
(31.00% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Seer to Participate in Upcoming November Investor Conferences

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management ...

13 days ago - GlobeNewsWire

Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript

Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript

14 days ago - Seeking Alpha

Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific

Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology Collaboration enhances unprecedented access to deep, unbiased proteomics ...

14 days ago - GlobeNewsWire

Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024

CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session with...

21 days ago - GlobeNewsWire

Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024

Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthro...

4 weeks ago - GlobeNewsWire

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

3 months ago - GlobeNewsWire

Seer Appoints Nicolas Roelofs to its Board of Directors

REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appo...

3 months ago - GlobeNewsWire

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference

REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

3 months ago - GlobeNewsWire

Seer to Report Second Quarter 2024 Financial Results on August 8, 2024

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

4 months ago - GlobeNewsWire

Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation

5 months ago - GlobeNewsWire

Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection Study

Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects Combined Workflow ...

6 months ago - GlobeNewsWire

Lab Instrument Industry Update - New Commercial Entrants

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry h...

6 months ago - Seeking Alpha

Seer Reports First Quarter 2024 Financial Results

Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications Demonstrated the power of the Proteograph Product Suite with a growing number o...

7 months ago - GlobeNewsWire

Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions

New Seer Technology Access Center to open in Bonn, Germany Provides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph™ Product Suite and mass spectrome...

7 months ago - GlobeNewsWire

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wi...

7 months ago - GlobeNewsWire

Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript

Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data

9 months ago - GlobeNewsWire

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

9 months ago - GlobeNewsWire

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies

10 months ago - GlobeNewsWire

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

10 months ago - GlobeNewsWire

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

11 months ago - GlobeNewsWire

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company man...

1 year ago - GlobeNewsWire

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics

1 year ago - GlobeNewsWire

Seer, Inc. (SEER) Q3 2023 Earnings Call Transcript

Seer, Inc. (NASDAQ:SEER) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - President, CEO David Horn - CFO Conference Call Partici...

1 year ago - Seeking Alpha

Seer Reports Third Quarter 2023 Financial Results

Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence Expanded access to the Proteograph™ Product Suite through t...

1 year ago - GlobeNewsWire